Quarterly ResultMay 12, 2026, 07:32 AM
Mereo BioPharma Q1 Net Loss Narrows to $6.7M; Clinical Updates
AI Summary
Mereo BioPharma reported a net loss of $6.7 million for the first quarter ended March 31, 2026, a significant reduction from $12.9 million in Q1 2025. The company held $36.2 million in cash and cash equivalents, projecting a cash runway into mid-2027. Key clinical updates include initiating regulatory discussions for setrusumab in pediatric patients following positive secondary endpoint data from Phase 3 studies, active partnership discussions for alvelestat's Phase 3 development, and partner āshibio's plan to start a Phase 2 trial for vantictumab in the second half of 2026.
Key Highlights
- Q1 2026 net loss narrowed to $6.7 million from $12.9 million in Q1 2025.
- Cash and cash equivalents totaled $36.2 million as of March 31, 2026.
- Company expects existing cash to fund operations into mid-2027.
- Setrusumab Phase 3 studies achieved high statistical significance in bone mineral density.
- Mereo initiated regulatory discussions for setrusumab in pediatric patients.
- Actively engaged in partnership discussions for alvelestat Phase 3 development.
- Vantictumab Phase 2 trial expected to commence in H2 2026 by partner āshibio.